Correlation Between Mineralys Therapeutics, and Lyell Immunopharma

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Lyell Immunopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Lyell Immunopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Lyell Immunopharma, you can compare the effects of market volatilities on Mineralys Therapeutics, and Lyell Immunopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Lyell Immunopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Lyell Immunopharma.

Diversification Opportunities for Mineralys Therapeutics, and Lyell Immunopharma

-0.07

Correlation Coefficient

Mineralys Therapeutics,  Lyell Immunopharma

Good diversification

The 3 months correlation between Mineralys and Lyell is -0.07. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Lyell Immunopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyell Immunopharma and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Lyell Immunopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyell Immunopharma has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Lyell Immunopharma go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Lyell Immunopharma

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 0.59 times more return on investment than Lyell Immunopharma. However, Mineralys Therapeutics, Common is 1.71 times less risky than Lyell Immunopharma. It trades about 0.02 of its potential returns per unit of risk. Lyell Immunopharma is currently generating about -0.09 per unit of risk. If you would invest  1,204  in Mineralys Therapeutics, Common on September 19, 2024 and sell it today you would earn a total of  0.50  from holding Mineralys Therapeutics, Common or generate 0.04% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	99.21%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Lyell Immunopharma

Mineralys Therapeutics,

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Lyell Immunopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lyell Immunopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Mineralys Therapeutics, and Lyell Immunopharma

The main advantage of trading using opposite Mineralys Therapeutics, and Lyell Immunopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Lyell Immunopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyell Immunopharma will offset losses from the drop in Lyell Immunopharma's long position.

The idea behind Mineralys Therapeutics, Common and Lyell Immunopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.